Reforgene named a 2025 Future Healthcare Top 100 company for the third consecutive year

Recently, the 2025 Future Healthcare Top 100 exhibition (2025VBEF), hosted by VBDATA, was successfully held in Suzhou. Themed "THE NOW: Critical Point", this edition interpreted the coexistence of "ice and fire" at the critical point and witnessed the pioneers who dare to stand in the present and break through boundaries. Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene"), focused on innovative R&D of gene editing medicines, was again selected into the 2025 Future Healthcare Top 100, Innovative Medicine and Biologics TOP100, following 2023 and 2024. Receiving this honor for three consecutive years is the recognition by industry experts and industry observation and analysis institutions of the professional hard power that Reforgene has accumulated over years in the field of innovative gene editing medicine R&D.

The so-called "critical point" is the inevitable result of the accumulation of countless small changes; like the lever of the times, once the threshold is crossed, even the smallest force can flip the entire structure. The critical point of innovative healthcare is also approaching. Together with peers in innovative healthcare, Reforgene will hold fast and break through at the critical point, adhere to the dual-drive strategy of breakthroughs in underlying gene editing technology and drug R&D, dedicate itself to the birth of curative medicines, and bring China's innovative solutions for genetic diseases and complex diseases to the world.

The Future Healthcare Top 100 list, founded in 2015 by VB100, VBDATA and Danke Research Institute, is the first domestic list for innovative healthcare companies targeting non-listed enterprises. It aims to select Chinese innovative healthcare providers that truly represent the future of healthcare, discover the core strength of China's future healthcare industry, and promote the innovation and transformation of the health industry. After eight years of practice and exploration, the "Future Healthcare Top 100" selection has received strong support and recognition from many investment institutions and enterprises, and has become an investment bellwether in the healthcare field, leading the development and investment trends of China's healthcare innovation now and for some time to come, providing reference for the subsequent financing of innovative enterprises.